ImageneBio (NASDAQ:IMA) Trading Down 1.3% - Time to Sell?

Key Points

• ImageneBio's stock fell by 1.3%, trading between $13.41 and $13.46 on a volume decrease from the average session.
• Analysts at Wedbush lowered their price target from $25.00 to $23.00 while maintaining a "neutral" rating, with overall consensus rating at "Moderate Buy."
• Recent insider trading saw Director David P. Bonita and Director Otello Stampacchia significantly increase their ownership stakes in the company with purchases at an average of $29.90 per share.

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) was down 1.3% on Thursday . The company traded as low as $13.41 and last traded at $13.46. Approximately 15,641 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 16,592 shares. The stock had previously closed at $13.64.

Analysts Set New Price Targets

Separately, Wedbush dropped their price target on shares of ImageneBio from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $35.50.

ImageneBio Trading Down 0.4%

The stock's fifty day simple moving average is $15.49 and its 200-day simple moving average is $15.34.

ImageneBio (NASDAQ:IMA - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08. On average, equities research analysts predict that ImageneBio, Inc. will post -0.91 EPS for the current fiscal year.

Insider Activity

In related news, Director Otello Stampacchia bought 267,556 shares of ImageneBio stock in a transaction that occurred on Friday, July 25th. The stock was acquired at an average price of $29.90 per share, for a total transaction of $7,999,924.40. Following the completion of the purchase, the director owned 454,982 shares in the company, valued at approximately $13,603,961.80. This represents a 142.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David P. Bonita bought 83,611 shares of ImageneBio stock in a transaction that occurred on Friday, July 25th. The stock was bought at an average price of $29.90 per share, with a total value of $2,499,968.90. Following the purchase, the director owned 287,885 shares of the company's stock, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The disclosure for this purchase can be found here. 5.94% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ImageneBio

Several hedge funds have recently made changes to their positions in IMA. JPMorgan Chase & Co. raised its position in ImageneBio by 18,244.1% in the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after purchasing an additional 154,892 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of ImageneBio by 21.0% during the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares during the last quarter. Northern Trust Corp grew its stake in shares of ImageneBio by 19.7% during the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of ImageneBio during the fourth quarter valued at approximately $72,000. Finally, Squarepoint Ops LLC bought a new position in ImageneBio in the fourth quarter valued at approximately $72,000. Institutional investors own 75.00% of the company's stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.